Finished dosage formulations · EU launch
Asia to European Union
Release-path recovery across an Asian CDMO network
A representative intervention for late analytical closure, fragmented ownership, and launch-critical documentation risk.
Executive context
The mandate behind the operating problem
A virtual pharmaceutical company was preparing an EU launch through an Asian CDMO while analytical testing, packaging readiness, deviation closure, and dossier evidence moved on separate timelines.
The operating problem was not a single delayed activity. It was the absence of one governed release path connecting site-level evidence to the company’s QP-readiness and launch decisions.
Intervention design
One governed path, not parallel status reports
01
Critical-path baseline from sampling through QP-ready dossier
02
Daily exception governance across QC, QA, packaging, and freight
03
Owner-level escalation thresholds for OOS, deviations, and missing evidence
04
Integrated release dashboard linking site dates to launch and dispatch windows
Daily
Exception review for testing, deviation, packaging, and document blockers.
Weekly
Cross-functional release-path review with accountable owners and recovery dates.
Gate-based
Evidence confirmation before QP-readiness, booking, and dispatch decisions.
Illustrative operating outcomes
Measured against a documented baseline
Targets are established after diagnostic baselining and verified through the evidence protocol below. They are not performance guarantees.
15–30%
Illustrative release-cycle compression target
100%
Critical release milestones assigned an owner
1
Integrated release-path baseline
Operating outcome
- Earlier visibility of release blockers and dependency collisions
- A single evidence status shared across site, company, and market teams
- Protected launch and dispatch decision windows
- A repeatable governance model for subsequent commercial batches
Evidence set
- Approved analytical status
- Deviation and OOS closure evidence
- QP-readiness document index
- Packaging and export-release confirmation
Related case studies
Continue through the operating scenarios
Confidential project review
Apply this governance model to your manufacturing gap
Share the product stage, market, and CMO/CDMO constraint. Elyzora will frame the critical path, evidence requirements, and intervention scope for qualification.
sales.elyzora@gmail.com